A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries

Background and Objective A probabilistic patient-level Markov model was previously developed to simulate lifetime clinical and economic outcomes of cinacalcet treatment in secondary hyperparathyroidism (SHPT) patients using local data from Italy. The present study extends the application of the model to four other European countries — Spain, Portugal, Switzerland and the Czech Republic — in order to assess the consistency of results.